Incyte Corporation (NASDAQ:INCY) announces five-year data from the Phase 3 COMFORT-I study evaluating the long-term safety and efficacy of Jakafi® (ruxolitinib) in patients with …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) and Incyte Corporation (NASDAQ:INCY) announced the entry into a definitive agreement for Incyte to acquire ARIAD’s European operations.
Incyte Corporation (NASDAQ: INCY) reported 2016 first-quarter financial results, including strong revenue growth driven by increased Jakafi® (ruxolitinib) sales in the U.S.
Healthcare analysts from Rodman and Renshow and Oppenheimer chimed in on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Incyte Corporation (NASDAQ:INCY), providing insights on …
Incyte Corporation (INCY:INCY) announced it has acquired the rights to develop and commercialize ruxolitinib (Jakafi®), its proprietary JAK1/JAK2 inhibitor, for graft-versus-host disease (GVHD) from …
Incyte Corporation (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a …
Incyte Corporation (NASDAQ:INCY) announced its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line …
Analysts weigh in with bullish sentiments on both Incyte Corporation (NASDAQ:INCY) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) following the termination of the drug trial …
Incyte Corporation (NASDAQ:INCY) announced that the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib in patients with relapsed or refractory metastatic …
Credit Suisse analyst Alethia Young came out today with new ratings and price targets on a handful of healthcare stocks. Let’s take a …
